The invention provides chroman compounds having formula 1 wherein R<;SUP>;1 <;/SUP>;is (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl, and independently R<;SUP>;1 <;/SUP>;has a cis-orientation in relation to the exocyclic phenyl group at the 2-position of the skeleton; R<;SUP>;4 <;/SUP>;is H, Hal, CF<;SUB>;3<;/SUB>;, OH or (1C-2C)alkyloxy; R<;SUP>;2<;/SUP>;, R<;SUP>;3<;/SUP>;, and R<;SUP>;5<;/SUP>;are independently H, Hal, CF<;SUB>;3<;/SUB>;, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl and prodrugs thereof for the manufacture of a medicine for estrogen-receptor related treatments.